Healthequity Overview
Latest ROE for Healthequity: 11.88% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow11.88%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for HQY is 11.88%. That is below the Technology sector average of 47.9%. Investors often review this figure alongside Healthequity's historical trend and sector peers before judging valuation or financial health.
Against Technology companies, HQY currently prints 11.88% for ROE, while the sector average sits near 47.9%. That is roughly 75.2% below the sector mean. Large gaps often invite a closer look at Healthequity's growth, margins, and balance sheet.
Return on Equity shows how effectively Healthequity converts resources into returns. At 11.88%, HQY may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting HQY's ROE (11.88%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Healthequity's ROE against similar Technology names. You can also browse sector and industry screens on Stockcircle for a broader set of Technology companies and their key multiples and fundamentals.
